Patents Examined by Jeffrey H Murray
-
Patent number: 12213978Abstract: The present invention relates to the fields of medicine and in particular cancer treatment. The invention more specifically relates to new compounds which are typically for use as a medicament. In particular, the invention relates to the use of these new compounds for increasing the presentation, typically the production and presentation, of Pioneer Translation Products (PTPs)-derived antigens by cells, in particular cancer cells, or changing the immunopeptidome, in a subject, and inducing or stimulating an immune response in the subject. The present disclosure also relates to uses of such compounds, in particular to prepare a pharmaceutical composition and/or to allow or improve the efficiency of a therapy in a subject in need thereof. The invention also discloses methods for treating a disease, in particular cancer, for preventing or treating cancer metastasis and/or cancer recurrence, in a subject.Type: GrantFiled: November 15, 2019Date of Patent: February 4, 2025Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT GUSTAVE ROUSSY, UNIVERSITE PARIS-SACLAYInventors: Sébastien Apcher, Mouad Alami, Romain Darrigrand, Samir Messaoudi, Valérie Salgues, Zafiarisoa Dolor Renko, Expedite Yen-Pon
-
Patent number: 12187740Abstract: The present invention relates to polymorphic forms of Bictegravir potassium of Formula II, process for their preparation and pharmaceutical composition comprising it.Type: GrantFiled: April 18, 2022Date of Patent: January 7, 2025Assignee: HONOUR LAB LIMITEDInventors: Kura Rathnakar Reddy, Kesireddy Subhash Chander Reddy, Guda Yadav Reddy
-
Patent number: 12187686Abstract: Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I, II, and II.Type: GrantFiled: September 9, 2019Date of Patent: January 7, 2025Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.Inventors: Ernst Schönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence, Gary Reuther
-
Patent number: 12180239Abstract: Organosilicon quaternary ammonium compounds, their formulations, including lyophilized solid formulations, and methods of use to treat infections in humans and animals.Type: GrantFiled: April 15, 2021Date of Patent: December 31, 2024Assignee: Topikos Scientific, Inc.Inventors: Gary Allred, Lanny Liebeskind, William R. Cast, Carl Hilliard
-
Patent number: 12180192Abstract: Disclosed herein are compounds of Formula I: TL-La-CE-HD??(I) or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IIa, IIb, IIIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is a moiety of Formula V or VI; where the substituents are as defined herein. Disclosed are also pharmaceutical compositions comprising the above compounds, and methods of treating disease by administering or contact a patient with one or more of the above compounds.Type: GrantFiled: May 25, 2021Date of Patent: December 31, 2024Assignee: Aligos Therapeutics, Inc.Inventors: Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, David McGowan, Jerome Deval
-
Patent number: 12178803Abstract: CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and poly-(ADP-ribose) polymerase (PARP) inhibitor. The CD47 blocking agent can be SIRP?Fc and the PARP inhibitor niraparib. The anti-cancer effect of niraparib is enhanced in the presence of SIRP?Fc. Specific combinations include SIRP?Fc forms that comprise an Fc that is either IgG1 or preferably IgG4 isotype. These combinations are useful particularly to treat solid tumours and blood cancers including lymphomas, leukemias and myelomas.Type: GrantFiled: August 29, 2019Date of Patent: December 31, 2024Assignee: Pfizer Inc.Inventors: Lisa Danae Schultz Johnson, Lei Cui
-
Patent number: 12171753Abstract: Provided herein are novel crystalline forms of a compound that acts as an ALDH2 effector, processes for preparing the crystalline forms of the compound with or without coformer, and uses thereof.Type: GrantFiled: June 10, 2022Date of Patent: December 24, 2024Assignee: Sophrosyne Pharmaceuticals LimitedInventors: Lewis Feldberg, Akram Sabouni, Thomas R. Bailey, Vincent Wing-Fai Tai, Tom Leyssens
-
Crystalline forms of 3-(5-(2-hydroxy-2-methylpropoxy)-6-methylpyrazin-2-yl)-1H-indole-7-carbonitrile
Patent number: 12168650Abstract: This disclosure provides crystalline forms of an androgen receptor modulator, and methods of making and using these forms.Type: GrantFiled: January 13, 2023Date of Patent: December 17, 2024Assignee: NIDO BIOSCIENCES, INC.Inventors: Bakary-Barry Toure, Magnus Ronn -
Patent number: 12162868Abstract: The present invention relates to novel piperazine derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially for targeted therapy treatment of hyperproliferative disorders, including benign hyperproliferative disorders, cancer and pre-cancer conditions.Type: GrantFiled: August 8, 2021Date of Patent: December 10, 2024Assignee: Vidac Pharma Ltd..Inventors: Paul Salama, Vered Behar, Oren Menahem Becker
-
Patent number: 12161643Abstract: The disclosure relates to stable topical pharmaceutical compositions of SHR0302 (also known as ARQ-250). In certain embodiments, pharmaceutical compositions of SHR0302 having a pH of less than about 4.6 have improved stability and do not exhibit crystal formation of the API. In certain embodiments, pharmaceutical compositions of SHR0302 comprising about 20% to about 30% dimethyl sulfoxide (DMSO) have improved stability and do not exhibit crystal formation of the API. The improved formulations of SHR0302 can exhibit acceptable commercial product shelf life and do not exhibit loss of potency of the API after prolonged storage.Type: GrantFiled: December 14, 2022Date of Patent: December 10, 2024Assignee: ARCUTIS BIOTHERAPEUTICS, INC.Inventors: Herbert R. Brinkman, Jason Michael Carbol
-
Patent number: 12162852Abstract: An object of the present invention is to provide a lactone compound having excellent water stability. Provided is a lactone compound represented by Formula (I). In Formula (I), R1 and R2 each independently represent a substituent which does not have a dissociative proton and has a Hammett's substituent constant ?p value of ?0.90 or more and ?0.03 or less. R3 represents a substituent which does not have a dissociative proton and has a Hammett's substituent constant ?p value of ?0.90 or more and ?0.03 or less, or a hydrogen atom. Y represents a substituent and n represents an integer of 1 to 4. In a case where n is an integer of 2 to 4, a plurality of Y's may be the same substituent or substituents different from each other.Type: GrantFiled: October 19, 2022Date of Patent: December 10, 2024Assignee: FUJIFILM CorporationInventor: Kazufumi Omura
-
Patent number: 12145913Abstract: Described herein are compounds and pharmaceutical compositions of phenyl-pyrimidinyl-urea derivatives, which inhibit the activity of Olig2. An example of a phenyl-pyrimidinyl-urea derivative has the following structure: Also described herein are methods using the Olig2 inhibitors for treating cancer and other diseases. The Olig2 inhibitors may be used to treat glioblastoma.Type: GrantFiled: April 19, 2021Date of Patent: November 19, 2024Assignee: CURTANA PHARMACEUTICALS, INC.Inventors: Graham Beaton, Stanton F. McHardy, Ambrosio Lopez, Jr., Bismarck Campos, Hua-Yu Leo Wang
-
Patent number: 12138258Abstract: The invention generally relates to solid forms of berberine ursodeoxycholate, and to pharmaceutical compositions, and methods of preparation and therapeutic use thereof. In particular, the invention relates to solid forms of berberine ursodeoxycholate and pharmaceutical compositions thereof useful in treating and/or preventing various diseases or disorders, including metabolic disorders, heart diseases, neurodegenerative diseases and liver diseases.Type: GrantFiled: February 23, 2021Date of Patent: November 12, 2024Assignee: SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD.Inventors: Meng Yu, Liping Liu, Xinxiang Fu
-
Patent number: 12134594Abstract: A composition is prepared from a platinum-based antitumor compound and a novel compound, and the novel compound is sodium(S)-2-(dithiocarboxylate ((2S, 3R, 4R, 5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-4-(methylthio)butyrate. The novel compound in the composition could effectively chelate the platinum-based antitumor compound and reduce the various adverse effects exhibited by the platinum-based compound. The dosage of the platinum-based antitumor compound can thus be increased, and the antitumor effect can be optimized. The novel compound itself is low-toxic and it has low chelating activities with essential metals in the human body; it would not impose significant adverse effects on the human body at given doses. The composition and its application as an antitumor drug overcome some technical drawbacks of platinum-based antitumor drugs, namely severe adverse effects and the development of drug resistance during administration.Type: GrantFiled: March 23, 2021Date of Patent: November 5, 2024Assignee: Guangdong Jianersheng Pharmaceutical Technology Co., Ltd.Inventors: Xiaojiang Tang, Xuefeng Ren, Yichen Ge, Zhiyong Zhong, Nina Zheng
-
Patent number: 12129254Abstract: Novel pyrimido[6?,1?:2,3]imidazo[4,5-b][1,6]naphthyridine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrimido[6?,1?:2,3]imidazo[4,5-b][1,6]naphthyridine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.Type: GrantFiled: December 12, 2023Date of Patent: October 29, 2024Assignee: KING FAISAL UNIVERSITYInventors: Christophe Tratrat, Michelyne Haroun
-
Patent number: 12128054Abstract: Aqueous pharmaceutical compositions, suitable for topical ophthalmic administration to a mammal, that comprise a therapeutically effective amount of a prostaglandin, less than 0.3% w/v, and no added benzalkonium chloride, are provided. Such compositions are useful in methods comprising their topical administration to mammalian subjects, e.g., humans and reducing intraocular pressure and/or ocular hyperemia in the patient. Such compositions are also useful in methods comprising their topical administration to mammalian subjects, e.g., humans and promoting eyelash growth in the patient.Type: GrantFiled: October 26, 2022Date of Patent: October 29, 2024Assignee: FAMYGEN LIFE SCIENCES, INC.Inventors: William Hite, Nilesh Parikh
-
Patent number: 12122786Abstract: The described compounds are of the class of cyclic nucleotides, both mono- and di-nucleotides, which play diverse roles in the prokaryotes and eukaryotes having the general formula which inhibit phosphodiesterases that inhibit cyclic mononucleotide or dinucleotides and/or both mononucleotide and dinucleotide. These compounds have potential diverse applications as antiviral, antibacterial, anti-inflammatory and anticancer agents, including cancer immunotherapy. Pharmaceutical compositions and methods for treating those kinase related diseases are within the scope of this invention.Type: GrantFiled: December 16, 2021Date of Patent: October 22, 2024Assignee: Purdue Research FoundationInventors: Herman O. Sintim, George Naclerio, Caroline Karanja
-
Patent number: 12122787Abstract: Disclosed in the present invention are a fused pyridone compound, and a preparation method therefor and a use thereof. Specifically, the present invention discloses a compound of formula (I-B), an optical isomer thereof and a pharmaceutically acceptable salt thereof, and the use of the compound as a KRAS inhibitor.Type: GrantFiled: January 25, 2023Date of Patent: October 22, 2024Assignees: SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD, JIANGXI JEMINCARE GROUP CO., LTDInventors: Shuchun Guo, Jun Fan, Yang Liu, Fang Bao, Jianbiao Peng, Haibing Guo
-
Patent number: 12109211Abstract: A sterile, ready-to-use pharmaceutical composition having hydralazine and/or a salt thereof at a concentration of less than about 20 mg/mL and a solvent comprising an organic co-solvent, wherein the hydralazine and/or salt thereof and the organic co-solvent are provided at a first weight ratio sufficient for the hydralazine and/or salt thereof to have a change in concentration of no more than about 10% after 2 months of storage at 60° C. Also described are methods of making and using the composition.Type: GrantFiled: December 27, 2022Date of Patent: October 8, 2024Assignee: ENDO OPERATIONS LIMITEDInventors: Kumaresh Soppimath, Tushar Hingorani, Hari A. Attluri, Harshil H. Jain
-
Patent number: 12110279Abstract: The present technology provides triazolones, tetrazolones, and imidazolones, or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolones, tetrazolones, and imidazolones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).Type: GrantFiled: April 21, 2022Date of Patent: October 8, 2024Assignee: Yuhan CorporationInventors: Hee Jae Tak, Eun Kyung Kim, Hyok Jun Cho, Cheol Hee Lim